Diagnostics Division: Key product launches in 2017

Instruments/ Devices			
Area	**Products**	**Description**	**Market**
Central laboratory	cobas 8000 - e 801 CCM High Speed	High throughput immunochemistry analyser cobas connection module (CCM) for up to 6000 samples/hour	US✓ WW*
Coagulation testing	cobas t 511/t 711	Medium and high volume coagulation systems	EU
Point of care	CoaguChek Vantus	Hand-held coagulation monitoring system for patient self-testing	US
Diabetes Care	Accu-Chek Instant bG System	Effortless, accurate and affordable blood glucose monitoring system	EU ✓
Tests			
Area	**Products**	**Description**	**Market**
HPV	cobas HPV	Next generation HPV DNA test leveraging 6800/8800 System automation to detect 14 high risk HPV genotypes with simultaneous detection of genotypes 16 and 18	EU✓
	CINtec Histology	Diagnostic component of the Roche cervical cancer portfolio	US ✓
Virology	cobas HIV 1+2 Qual	For use on the cobas 6800/8800 Systems; for diagnosis of acute HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection	EU
Sequencing	AVENIO ctDNA Panels	Liquid biopsy for circulating tumor DNA, 3 panels: targeted panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes)	EU/US
cobas Liat	cobas Liat C.Diff	Qualitative IVD test that utilises real-time PCR for the direct detection of the tcdB gene of toxigenic *Clostridium difficile (C.Diff.)* in unformed stool specimens	EU✓
	cobas Liat MRSA/SA	Qualitative IVD test that utilises real-time PCR for the direct detection of MRSA and *Staphylococcus aureus* DNA from nasal swabs	EU
Women's health	AMH	Immunoassay for the *in vitro* quantitative determination of anti-Mullerian hormone (AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics	US✓
Companion diagnostics	PD-LI (SP142) for Bladder cancer**	Complementary diagnostic for Tecentriq	EU
	PD-L1 (SP142) for NSCLC**	Complementary diagnostic for Tecentriq	EU

* WW – world wide. | ** Achieve commercial readiness, dependent on Pharma label and approval.